Antimalarial drug discovery — approaches and progress towards new medicines
暂无分享,去创建一个
Elizabeth A. Winzeler | Erika L. Flannery | E. Winzeler | A. Chatterjee | Arnab K. Chatterjee | E. Flannery
[1] P. Rathod,et al. High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.
[2] S. Abdulla,et al. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children , 2009, Malaria Journal.
[3] C. Siethoff,et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials , 2012, British journal of clinical pharmacology.
[4] B. K. Park,et al. Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. , 2010, Angewandte Chemie.
[5] R. Sinden,et al. Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay. , 2012, International journal for parasitology.
[6] E. Winzeler,et al. Genetic Analysis of Primaquine Tolerance in a Patient with Relapsing Vivax Malaria , 2013, Emerging infectious diseases.
[7] T. Wells. Natural products as starting points for future anti-malarial therapies: going back to our roots? , 2011, Malaria Journal.
[8] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[9] Xiang-Lei Yang,et al. ATP-Directed Capture of Bioactive Herbal-Based Medicine on Human tRNA Synthetase , 2012, Nature.
[10] David M. Shackleford,et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. , 2011, Journal of medicinal chemistry.
[11] K. Williamson,et al. A High-Throughput Screen Targeting Malaria Transmission Stages Opens New Avenues for Drug Development , 2011, The Journal of infectious diseases.
[12] C. Biot,et al. Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action , 2008, Molecules.
[13] Joana C. Silva,et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia , 2012, Proceedings of the National Academy of Sciences.
[14] Yingyao Zhou,et al. Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery , 2011, Science.
[15] K. Cimanga,et al. Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 1: a clinical phase IIA trial. , 2012, Planta medica.
[16] A. Vaughan,et al. Malaria parasite development in the mosquito and infection of the mammalian host. , 2009, Annual review of microbiology.
[17] C. Holland,et al. Ascaris co-infection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children , 2013, Malaria Journal.
[18] M. Enserink. If artemisinin drugs fail, what's plan B? , 2010, Science.
[19] X. Su,et al. A Class of Tricyclic Compounds Blocking Malaria Parasite Oocyst Development and Transmission , 2012, Antimicrobial Agents and Chemotherapy.
[20] Silvia Parapini,et al. A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. , 2013, The Journal of antimicrobial chemotherapy.
[21] L. H. Schmidt,et al. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. , 1977, The American journal of tropical medicine and hygiene.
[22] S. Hoffman,et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.
[23] N. White. Cardiotoxicity of antimalarial drugs. , 2007, The Lancet. Infectious diseases.
[24] V. A. Stewart,et al. Immune mechanisms in malaria: new insights in vaccine development , 2013, Nature Medicine.
[25] E. McGraw,et al. Beyond insecticides: new thinking on an ancient problem , 2013, Nature Reviews Microbiology.
[26] Danny W. Wilson,et al. Cell-Cell Communication between Malaria-Infected Red Blood Cells via Exosome-like Vesicles , 2013, Cell.
[27] S. Apers,et al. Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract. , 2010, Journal of ethnopharmacology.
[28] S. Meshnick,et al. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. , 1994, Experimental parasitology.
[29] C. Fang,et al. Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[30] E. Winzeler,et al. Validation of isoleucine utilization targets in Plasmodium falciparum , 2011, Proceedings of the National Academy of Sciences.
[31] Serge Batalov,et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum , 2009, Genome Biology.
[32] M. Toner,et al. Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. , 2013, Cell host & microbe.
[33] L. Rénia,et al. A pre-emptive strike against malaria's stealthy hepatic forms , 2009, Nature Reviews Drug Discovery.
[34] L. Shultz,et al. Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.
[35] B. Fermini,et al. The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.
[36] G. van Gemert,et al. The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito Vector , 2012, Antimicrobial Agents and Chemotherapy.
[37] E. Beutler,et al. The hemolytic effect of primaquine and related compounds: a review. , 1959, Blood.
[38] O. Gaye,et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial , 2010, The Lancet.
[39] David M. Shackleford,et al. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. , 2011, Journal of medicinal chemistry.
[40] E. Winzeler,et al. The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites , 2012, PLoS medicine.
[41] J. Lelièvre,et al. Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence “Transmission Blocking” Assay , 2012, Malaria Journal.
[42] K. Kuhen,et al. Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents , 2011, Journal of medicinal chemistry.
[43] Yongyuth Yuthavong,et al. A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.
[44] Ana Rodriguez,et al. The silent path to thousands of merozoites: the Plasmodium liver stage , 2006, Nature Reviews Microbiology.
[45] Guoli Zhou,et al. Wolbachia Invades Anopheles stephensi Populations and Induces Refractoriness to Plasmodium Infection , 2013, Science.
[46] Félix Calderón,et al. A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold. , 2012, ACS medicinal chemistry letters.
[47] Peter G. Schultz,et al. A Chemical Genomic Analysis of Decoquinate, a Plasmodium falciparum Cytochrome b Inhibitor , 2011, ACS chemical biology.
[48] D. Koop,et al. Optimization of endochin-like quinolones for antimalarial activity. , 2011, Experimental parasitology.
[49] A. Janowsky,et al. Discovery of dual function acridones as a new antimalarial chemotype , 2009, Nature.
[50] Bruce Russell,et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription , 2011, BMC Genomics.
[51] J. Stockman. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .
[52] M. Mota,et al. The Next Opportunity in Anti-Malaria Drug Discovery: The Liver Stage , 2011, PLoS pathogens.
[53] Yongyuth Yuthavong,et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target , 2012, Proceedings of the National Academy of Sciences.
[54] F. Nosten,et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.
[55] J. Kevin Baird,et al. Resistance to Therapies for Infection by Plasmodium vivax , 2009, Clinical Microbiology Reviews.
[56] Elizabeth A. Winzeler,et al. Na+ Regulation in the Malaria Parasite Plasmodiumfalciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials , 2013, Cell host & microbe.
[57] Anang A. Shelat,et al. Chemical genetics of Plasmodium falciparum , 2010, Nature.
[58] David M. Shackleford,et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. , 2009, Journal of medicinal chemistry.
[59] Cécilie Martin,et al. Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug , 2012, The Journal of infectious diseases.
[60] James R. Brown,et al. Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.
[61] Christian Scheurer,et al. Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.
[62] W. Milhous,et al. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. , 1993, Annals of tropical medicine and parasitology.
[63] Kami Kim,et al. Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites. , 2009, The Journal of infectious diseases.
[64] V. Avery,et al. Whole-cell in vitro screening for gametocytocidal compounds. , 2012, Future medicinal chemistry.
[65] Miguel Prudêncio,et al. Liver-stage malaria parasites vulnerable to diverse chemical scaffolds , 2012, Proceedings of the National Academy of Sciences.
[66] Christian Scheurer,et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.
[67] Trixie Wagner,et al. Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria , 2010, Journal of medicinal chemistry.
[68] Bradley I. Coleman,et al. Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model* , 2010, The Journal of Biological Chemistry.
[69] M. Dixon,et al. Sex in Plasmodium: a sign of commitment. , 2008, Trends in parasitology.
[70] Choukri Ben Mamoun,et al. Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission , 2013, Proceedings of the National Academy of Sciences.
[71] P. Wilairat,et al. Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening , 2004, Antimicrobial Agents and Chemotherapy.
[72] P. Newton,et al. A Major Genome Region Underlying Artemisinin Resistance in Malaria , 2012, Science.
[73] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[74] D. Diallo,et al. Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications. , 2010, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[75] Bradley I. Coleman,et al. Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. , 2011, Chemistry & biology.
[76] Balbir Singh,et al. Human Infections and Detection of Plasmodium knowlesi , 2013, Clinical Microbiology Reviews.
[77] Francisco-Javier Gamo,et al. Global phenotypic screening for antimalarials. , 2012, Chemistry & biology.
[78] Richard J Sciotti,et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine , 2012, Malaria Journal.
[79] K. Rieckmann,et al. Simple In Vitro Assay for Determining the Sensitivity of Plasmodium vivax Isolates from Fresh Human Blood to Antimalarials in Areas where P. vivax Is Endemic , 2003, Antimicrobial Agents and Chemotherapy.
[80] G. Evans,et al. Plasmodium falciparum Parasites Are Killed by a Transition State Analogue of Purine Nucleoside Phosphorylase in a Primate Animal Model , 2011, PloS one.
[81] P. Olliaro,et al. The Global Portfolio of New Antimalarial Medicines Under Development , 2009, Clinical pharmacology and therapeutics.
[82] R. Sauerwein,et al. A Plant-Derived Morphinan as a Novel Lead Compound Active against Malaria Liver Stages , 2006, PLoS medicine.
[83] J. Burrows,et al. The global pipeline of new medicines for the control and elimination of malaria , 2012, Malaria Journal.
[84] K. Williamson,et al. A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. , 2011, Molecular and biochemical parasitology.
[85] M. Fay,et al. Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays , 2013, PloS one.
[86] Gilean McVean,et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia , 2013, Nature Genetics.
[87] R. Sinden,et al. A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. , 2012, International journal for parasitology.
[88] Marcel Tanner,et al. Malaria eradication back on the table. , 2008, Bulletin of the World Health Organization.
[89] M. Mota,et al. Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins , 2013, Proceedings of the National Academy of Sciences.
[90] M. Tanner,et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. , 2002, The American journal of tropical medicine and hygiene.
[91] P. Rathod,et al. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. , 1982, Molecular and biochemical parasitology.
[92] C. Rogier,et al. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. , 2011, ACS chemical biology.
[93] Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa , 2013, Malaria Journal.
[94] V. Yardley,et al. Antiparasitic Activities and Toxicities of Individual Enantiomers of the 8-Aminoquinoline 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-Dichlorophenoxy]Quinoline Succinate , 2008, Antimicrobial Agents and Chemotherapy.
[95] C. Harris,et al. The Design and Application of Target-Focused Compound Libraries , 2011, Combinatorial chemistry & high throughput screening.
[96] K. Kain,et al. Tafenoquine: a promising new antimalarial agent , 2007, Expert opinion on investigational drugs.
[97] K. Cimanga,et al. Antimalarial Efficacy of a Quantified Extract of Nauclea pobeguinii Stem Bark in Human Adult Volunteers with Diagnosed Uncomplicated falciparum Malaria. Part 2: A Clinical Phase IIB Trial , 2012, Planta Medica.
[98] R. Sinden,et al. Assessing transmission blockade in Plasmodium spp. , 2013, Methods in molecular biology.
[99] Bruce Russell,et al. Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.
[100] J. Burrows,et al. Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.
[101] A. Thomas,et al. Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.
[102] Kwaku Poku Asante,et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.
[103] José María Bueno,et al. An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. , 2011, ACS medicinal chemistry letters.
[104] D. Wirth,et al. Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2008, Journal of Biological Chemistry.
[105] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.
[106] Peter G. Schultz,et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.
[107] David M. Shackleford,et al. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. , 2012, Journal of medicinal chemistry.
[108] K. Kuhen,et al. Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial Agents , 2012, Journal of medicinal chemistry.
[109] J. Chollet,et al. Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. , 2013, Journal of medicinal chemistry.
[110] John A. Tallarico,et al. Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin , 2012, Cell host & microbe.
[111] Leann Tilley,et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion , 2011, Proceedings of the National Academy of Sciences.
[112] Jeremy N. Burrows,et al. Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen , 2011, Antimicrobial Agents and Chemotherapy.
[113] Simon J F Macdonald,et al. Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). , 2011, ACS medicinal chemistry letters.
[114] Nancy Fullman,et al. Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.
[115] William J. Welsh,et al. Structure-based Design of Novel Small-Molecule Inhibitors of Plasmodium falciparum , 2010, J. Chem. Inf. Model..
[116] Yu Wang,et al. Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. , 2011, Molecular and biochemical parasitology.
[117] V. Avery,et al. Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening , 2012, The American journal of tropical medicine and hygiene.
[118] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[119] S. Puri,et al. Inhibition of the development of the hepatic stages of Plasmodium yoelii nigeriensis by antihistaminic agents. , 1999, Annals of tropical medicine and parasitology.
[120] Ogobara K. Doumbo,et al. A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.
[121] L. H. Schmidt. Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys , 1983, Antimicrobial Agents and Chemotherapy.
[122] F. Muregi,et al. Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design , 2009, Drug development research.
[123] A. Vaughan,et al. That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda , 2010, Science.
[124] D. Warhurst,et al. The chemotherapy of rodent malaria. XLIV. Studies on the mode of action of CM 6606, an indolo (3,2-c) quinoline N-oxide. , 1989, Annals of tropical medicine and parasitology.
[125] T. Spicer,et al. A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes. , 2011, Molecular and biochemical parasitology.
[126] R. Moreira,et al. Primaquine revisited six decades after its discovery. , 2009, European journal of medicinal chemistry.
[127] Caroline W. Kabaria,et al. The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009 , 2010, PLoS neglected tropical diseases.
[128] Yuexin Li,et al. Quinolone-3-Diarylethers: A New Class of Antimalarial Drug , 2013, Science Translational Medicine.